Morningstar

SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis

Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the subcutaneous (SC) administration ...
The New England Journal of Medicine

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) ...
Morningstar

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity ...

SPRING HOUSE, Pa., Jan. 6, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic ...
Detroit News

Dr. Roach: Understanding how systemic lupus affects a person's body

Dear Dr. Roach: What is lupus, and what does it do to your body? I just had a friend diagnosed with it after many months of tests. — T.S.B. Dear T.S.B.: The term "lupus" generally means systemic lupus ...